Atezolizumab

Tecentriq®

Atezolizumab is an IgG1κ antibody that stimulates T-cell activation and proliferation by binding to PD-L1.

10/2020

Tecentriq is indicated in combination with cobimetinib and vemurafenib for metastatic or unresectable melanoma with BRAF V600E mutation.

Differential blood count, chemogram (Na, K, chloride, calcium, phosphate, urea, creatinine, uric acid, bilirubin, ASAT, ALAT, gamma-GT, alkaline phosphatase, LDH, pancreatic amylase, total protein, CRP, CK), glucose, cortisol, TSH, fT4, hs-troponin T, troponin I, NT-proBNP, S-100, pregnancy test, ECG, echocardiography (in case of cardiovascular risk).

Before each administration: differential blood count, chemogram (Na, K, chloride, calcium, phosphate, urea, creatinine, uric acid, bilirubin, ASAT, ALAT, gamma-GT, alkaline phosphatase, LDH, pancreatic amylase, total protein, CRP, CK), glucose; every 2 months: TSH, fT4.

i.v. infusion over 60 minutes 840 mg every 2 weeks in combination with cobimetinib and vemurafenib.

For the treatment of melanoma, Tecentriq® should be taken until disease progression or the occurrence of unacceptable toxicity.

See the specialist literature, guidelines and study results.

Women: negative pregnancy test, double contraception until 120 days after the last infusion, offer reproductive counselling.

Men: adequate contraception until 120 days after the last infusion, offer reproductive counselling.

No live vaccines 30 days before starting therapy and during treatment.